DAY 29:
The amount of time it took SARS-COV-2 to clear did not differ significantly between the Molnupiravir group and the placebo group. (WMD: 1.62; 95% CI; [0.69,3.80] p=0.27; I²=0%) (P-value for subgroup differences = 0.84). (Fig 3C)
Overall: No significant outcome reported in pooled analysis of molnupiravir 200 mg dose (WMD: 1.33; 95% CI; [0.80, 2.20] p=0.27; I²=0%).
Figure 4: Mean change in SARS-COV-2 RNA viral load from baseline in nasopharyngeal sample: